secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2024-12-16T23:59:59+00:00
Accession:  0000950170-24-136680
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics appoints Isabel Kalofonos as CCO ahead of paltusotine launch
----------------------------------------------------------------------

- Isabel Kalofonos named Chief Commercial Officer, effective Dec 16, 2024; leads paltusotine (once-daily SST2 agonist for acromegaly) launch prep and pipeline commercialization.
- Compensation: $500k base salary, 40% target bonus; severance includes 9-month base pay (12-month + full target bonus if change in control within 12 months).
- Expected Jan 10, 2025 grant of stock option for 100,000 shares; 25% vests Dec 16, 2025, remainder in 36 monthly installments.
- Ms. Kalofonos previously CCO at Fulcrum Therapeutics; led ELAHERE launch at ImmunoGen and TAKHZYRO global launch at Takeda/Shire.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017024136680/0000950170-24-136680-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017024136680/crnx-20241216.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-136680

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer